368879-17-8

Basic information

• Product Name: 1-(4-Bromobenzyl)-4-methylpiperazine
• Synonyms: 1-(4-Bromobenzyl)-4-methylpiperazine;Piperazine, 1-[(4-bromophenyl)methyl]-4-methyl-;1-Methyl-4-(4-(4,4,5,5-tetraMethyl-l,3,2-dioxaborolan-2-yl)benzyl)piperazine
• CAS NO: 368879-17-8
• Molecular Formula: C₁₂H₁₇BrN₂
• Molecular Weight: 269.18
• Product Categories: Aryl;Organohalides;alkyl bromide
• Mol File: 368879-17-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 325.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.325±0.06 g/cm3(Predicted)
• PKA: 7.57±0.10(Predicted)
• CAS DataBase Reference: 1-(4-Bromobenzyl)-4-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Bromobenzyl)-4-methylpiperazine(368879-17-8)
• EPA Substance Registry System: 1-(4-Bromobenzyl)-4-methylpiperazine(368879-17-8)

Safety Data

• Hazardous Substances Data: 368879-17-8(Hazardous Substances Data)

Usage

General Description

1-(4-Bromobenzyl)-4-methylpiperazine is a chemical compound which belongs to the class of organic compounds known as piperazines. Piperazines are compounds containing a piperazine ring, which is a saturated aliphatic six-member ring with two nitrogen atoms at opposite positions, and characterized by the functional group C4H10N2. This specific compound has a bromobenzyl group attached to one of the nitrogen atoms and a methyl group attached to the other. Its molecular formula is C12H16BrN2. It is typically used in scientific and industrial settings, and it may be involved in the synthesis of various pharmaceuticals and other complex organic compounds. However, its properties and specific uses may vary widely depending on its exact context. As a chemical compound, it should be handled with appropriate safety measures.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 91345-62-9 1-(4-bromobenzyl)piperazine 
• 74-88-4 methyl iodide 
• 64-18-6 formic acid 

Downstream Products

• 890657-53-1 N-(4-methylphenyl)-4-(4-methylpiperazinyl-1-methyl)benzamide 
• 581076-63-3 N-(3-amino-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide 
• 938043-30-2 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine 
• 1275579-59-3 bis{4-[N-(N-methylpiperazinyl)methyl]phenyl}phosphine oxide 
• 1262791-03-6 1,2-bis(bis{4-[(4-methylpiperazin-1-yl)methyl]phenyl}phosphino)ethane 

Relevant articles and documents

Novel 3-(substituted amino)-6-alkyl-pyrazine-2-carboxamide derivatives and use thereof

A novel 3 -6 - alkyl-pyrazine -2 - carboxamide derivative or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing or treating MerTTK-related diseases and a method for preventing or treating MerTTK-related diseases contains the same as an active ingredient.

Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor

The phosphoinositide 3-kinase (PI3K) family is one of the most frequently activated enzymes in a wide range of human cancers; thus, inhibition of PI3K represents a promising strategy for cancer therapy. Herein, a series of benzylamine substituted arylsulfonamides were designed and synthesized as dual PI3K/mTOR inhibitors using a strategy integrating focused library design and virtual screening, resulting in the discovery of 13b (NSC765844). The compound 13b exhibits highly potent enzyme inhibition with IC50s of 1.3, 1.8, 1.5, 3.8 and 3.8?nM for PI3Kα, β, γ, δ, and mTOR, respectively. 13b was further evaluated in NCI by an in?vitro cytotoxic screening program. Broad-spectrum antitumor activities with mean GI50value of 18.6?nM against approximately 60 human tumor cell lines were found. 13b displayed favorable physicochemical properties and superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in?vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug candidate.

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS

The invention relates to compounds of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.